Metabolic syndrome: Diabetes and cardiovascular disease

Indian Heart Journal

Volumn 58, Issue 2, 2006, Pages 149-152

  Gupta, Sanjiv ^a   Gupta, Brig M M ^b  

^a Tongia Heart and General Hospital ^*  (India)

^b ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

Dyslipidemias; Impaired glucose tolerance; Insulin resistance

Indexed keywords

ACARBOSE; ATORVASTATIN; DEXAMPHETAMINE; DEXFENFLURAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENFLURAMINE; FENOFIBRATE; FLUOXETINE; GEMFIBROZIL; GLITAZONE DERIVATIVE; IRBESARTAN; METFORMIN; NICOTINIC ACID; PHENTERMINE; PIOGLITAZONE; ROSIGLITAZONE; ROSUVASTATIN; SIBUTRAMINE; SIMVASTATIN; SULFONYLUREA; TELMISARTAN; TETRAHYDROLIPSTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG FORMULATION; DYSLIPIDEMIA; EXERCISE; FEEDING BEHAVIOR; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; OBESITY; RISK FACTOR;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFE STYLE; METABOLIC SYNDROME X; RISK FACTORS;

EID: 33749549666     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. WHO Expert Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of WHO consultation 1999.
2. NCEP expert panel in detection, evaluation and treatment of high blood pressure in adults - executive summary of the third report of The National Cholesterol Education Programme (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. International Diabetes Federation - The IDF consensus world wide definition of the metabolic syndrome. http:/www.idf.org (14 April 2005).
4. Quoted by DA Wood "Guidelines on cardiovascular risk assessment and management". Eur Heart J 2005;7(Suppl):L5-L10.
5. WHO Expert Consultation. Appropriate body mass index for Asian population and its implications for policy and interventional strategies. Lancet 2004;363:157-63.
6. Misra A, Vikram NK. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians - evidence and implications. Nutrition 2004;20:482-91.
7. Deepa R, Shanthirani CS, Premlatha G, Sastry NG, Mohan V. Prevalence of insulin resistance syndrome in a selected south Indian population - the Chennai urban population study (CUPS 7). Indian J Med Res 2002;115:118-27.
8. Joshi SR. Metabolic syndrome - emerging cluster of the Indian phenotype. J Assoc Phys India 2003;51:445-46.
9. Lindstrom J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS). Life style intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-36.
10. Torgeson JS, Hauptman J, Boldrin MN. Xenical in the prevention of diabetes in obese subjects (XENDOS Study). A randomized study of orlistat as an adjunct to life style changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155-61.
11. James W, Philip T. The SCOUT Study. Risks benefit profile of sibutramine in overweight high risk cardiovascular patients. Eur Heart J 2005;7(Suppl):L44-48.
12. United Kingdom Prospective Study (UKPDS) Group. Intensive blood glucose control with sulphonlyurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
13. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patient with type 2 diabetes. N Engl J Med 2003;348:383-93.
14. The Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effect of an angiotensin converting enzyme inhibitor - ramipril on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
15. Collins R, Armitage J, Parish S, Sleigh P, Leto R. MRC/BHF Heart Protection Study (HPS) of cholesterol lowering with simvastatin in 5963 people with diabetes - a randomized placebo controlled trial. Lancet 2003;361:2005-16.
16. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes - The Diabetes Atherosclerosis Intervention Study (DAIS) - a randomized study. Lancet 2001;357:905-10.
17. Reasner CA. Niaspan, a powerful treatment option for diabetic dyslipidemia. Eur Heart J 2005;7(Suppl):F48-55.
18. Stalenhoef AFH, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome - results of the COMETS study. Eur Heart J 2005;26:2664-72.